drugset / Trial / NCT03716427
Drug Interaction Study of CT1812 in Healthy Volunteers
SequentialOpen-labelTreatment
Summary
This is Phase 1, single-center, open-label, single-sequence drug-drug interaction study to determine the effect of CT1812 (560 mg) once daily on the pharmacokinetics of 4 probe drugs (tolbutamide, midazolam, dextromethorphan and omeprazole).
Timeline
- Start
- 2016-11-10
- Primary completion
- 2016-12-27
- Completion
- 2017-02-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CT1812 | Small molecule | 560 mg | — |
| Subject | Dextromethorphan | Unknown | — | — |
| Subject | Midazolam | Small molecule | — | — |
| Subject | Omeprazole | Other / unclassified | — | — |
| Subject | Tolbutamide | Small molecule | — | — |
Indications
No indication recorded.